THERAPY FOR RHINOVIRUS

There is still no clinically effective specific antirhinovirus therapy, but research is active. Prophylaxis against rhinovirus infections of volunteers, first demonstrated with interferons, has now been induced with synthetic molecules that act by binding to a hydrophobic pocket in the virus capsid. Further work will be needed to show a therapeutic effect against more serotypes and in field conditions. Antireceptor antibodies also block infection and need further study. Nonspecific treatments, for example with nedocromil, show limited clinical benefit.